Published in Ann Intern Med on October 15, 1991
Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev (2005) 15.72
beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev (1995) 12.53
An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev (1993) 8.03
AmpC beta-lactamases. Clin Microbiol Rev (2009) 7.14
Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev (1997) 4.32
Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest (2003) 3.31
Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother (1992) 3.31
Bundled care for septic shock: an analysis of clinical trials. Crit Care Med (2010) 2.57
Outbreak of TEM-24-producing Enterobacter aerogenes in an intensive care unit and dissemination of the extended-spectrum beta-lactamase to other members of the family enterobacteriaceae. J Clin Microbiol (1996) 2.52
Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev (2011) 2.46
Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother (2008) 2.38
Plasmid-mediated resistance to expanded-spectrum cephalosporins among Enterobacter aerogenes strains. Antimicrob Agents Chemother (1998) 2.03
Clinical and bacteriological study of nosocomial infections due to Enterobacter aerogenes resistant to imipenem. J Clin Microbiol (1993) 1.94
Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev (2012) 1.84
Molecular epidemiology of Enterobacter aerogenes acquisition: one-year prospective study in two intensive care units. J Clin Microbiol (1996) 1.73
Extended-spectrum beta-lactamases among Enterobacter isolates obtained in Tel Aviv, Israel. Antimicrob Agents Chemother (2005) 1.67
Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob Agents Chemother (2004) 1.65
Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis (2011) 1.64
Extended-spectrum beta-lactamase enzymes in clinical isolates of Enterobacter species from Lagos, Nigeria. J Clin Microbiol (2003) 1.62
How do you choose antibiotic treatment? BMJ (1999) 1.60
Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care (2010) 1.57
Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother (1992) 1.57
Beta-lactamases and detection of beta-lactam resistance in Enterobacter spp. Antimicrob Agents Chemother (1997) 1.44
Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother (2001) 1.44
Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother (2011) 1.41
Clinical characteristics and outcomes of spontaneous bacterial peritonitis caused by Enterobacter species versus Escherichia coli: a matched case-control study. BMC Infect Dis (2016) 1.40
Extended-spectrum β-lactamases in Gram Negative Bacteria. J Glob Infect Dis (2010) 1.39
Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother (2007) 1.28
Bacteremia due to extended-spectrum-beta-lactamase-producing Enterobacter cloacae: role of carbapenem therapy. Antimicrob Agents Chemother (2010) 1.16
Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis (2003) 1.15
New beta-lactams: new problems for the internist. Ann Intern Med (1991) 1.15
Successive emergence of Enterobacter aerogenes strains resistant to imipenem and colistin in a patient. Antimicrob Agents Chemother (2005) 1.14
SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae. J Clin Microbiol (2005) 1.13
Bacteraemia in the adult intensive care unit of a teaching hospital in Nottingham, UK, 1985-1996. Eur J Clin Microbiol Infect Dis (1998) 1.13
Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams. Antimicrob Agents Chemother (1998) 1.10
Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients. Antimicrob Agents Chemother (2003) 1.09
The epidemiology of antimicrobial resistance in hospital acquired infections: problems and possible solutions. BMJ (1998) 1.08
Prevalence, microbiology, and clinical characteristics of extended-spectrum beta-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii in Korea. Eur J Clin Microbiol Infect Dis (2007) 1.08
Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model. Antimicrob Agents Chemother (1995) 1.05
Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens. Antimicrob Agents Chemother (1997) 1.05
Inducible beta-lactam resistance in Aeromonas hydrophila: therapeutic challenge for antimicrobial therapy. J Clin Microbiol (1998) 1.04
Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. BMC Infect Dis (2012) 1.01
Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother (2011) 1.00
Persistent Staphylococcus aureus bacteremia: a prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates. Medicine (Baltimore) (2013) 1.00
Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae. Antimicrob Agents Chemother (2000) 0.99
Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains. Antimicrob Agents Chemother (1998) 0.96
A case of bilateral endogenous Pantoea agglomerans endophthalmitis with interstitial lung disease. Korean J Ophthalmol (2010) 0.96
Risk factors for acquisition of multiply drug-resistant gram-negative bacteria. Eur J Clin Microbiol Infect Dis (1994) 0.95
Pneumococcal colonisation density: a new marker for disease severity in HIV-infected adults with pneumonia. BMJ Open (2014) 0.93
Infective endocarditis due to Stenotrophomonas (Xanthomonas) maltophilia. Eur J Clin Microbiol Infect Dis (1998) 0.92
Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob Agents Chemother (1996) 0.92
Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis (2014) 0.92
Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother (2003) 0.92
Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp. J Clin Microbiol (2005) 0.91
Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study. Antimicrob Agents Chemother (2012) 0.89
The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock. Virulence (2013) 0.89
Clinical features, risk factors and outcomes of bacteremia due to enterococci with high-level gentamicin resistance: comparison with bacteremia due to enterococci without high-level gentamicin resistance. J Korean Med Sci (2009) 0.88
Clinical management of infections caused by multidrug-resistant Enterobacteriaceae. Ther Adv Infect Dis (2013) 0.88
[Diagnosis and therapy of sepsis]. Clin Res Cardiol (2006) 0.87
Microbiological surveillance and parenteral antibiotic use in a critical care unit. Can J Infect Dis (2000) 0.87
Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-associated methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2013) 0.86
An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy. Virulence (2013) 0.86
Postneurosurgical meningitis due to Proteus penneri with selection of a ceftriaxone-resistant isolate: analysis of chromosomal class A beta-lactamase HugA and its LysR-type regulatory protein HugR. Antimicrob Agents Chemother (2002) 0.86
Nursing home residents and Enterobacteriaceae resistant to third-generation cephalosporins. Emerg Infect Dis (2004) 0.85
Enterobacter taylorae, a new opportunistic pathogen: report of four cases. J Clin Microbiol (1993) 0.84
Temporal trends in Enterobacter species bloodstream infection: a population-based study from 1998-2007. Clin Microbiol Infect (2011) 0.84
Evaluation of ceftriaxone utilization at multicenter study. Korean J Intern Med (2009) 0.83
Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species. Antimicrob Agents Chemother (2016) 0.83
Plasmid-mediated Extended-spectrum beta-Lactamases in Organisms Other Than Klebsiella pneumoniae and Escherichia coli: A Hidden Reservoir of Transferable Resistance Genes. Curr Infect Dis Rep (2002) 0.83
Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study: healthcare-associated Gram-negative BSI. Eur J Clin Microbiol Infect Dis (2011) 0.82
Complex Regulation Pathways of AmpC-Mediated β-Lactam Resistance in Enterobacter cloacae Complex. Antimicrob Agents Chemother (2015) 0.82
Risk and Prognostic Factors for Multidrug-Resistant Acinetobacter Baumannii Complex Bacteremia: A Retrospective Study in a Tertiary Hospital of West China. PLoS One (2015) 0.81
Clinical Features and Rate of Infective Endocarditis in Non-Faecalis and Non-faecium Enterococcal Bacteremia. Chonnam Med J (2011) 0.81
Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. BMC Pharmacol Toxicol (2013) 0.81
The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies. Leuk Lymphoma (2016) 0.80
Early oral antibiotic switch compared with conventional intravenous antibiotic therapy for acute cholangitis with bacteremia. Dig Dis Sci (2014) 0.80
Comparison in a rat thigh abscess model of imipenem, meropenem and cefoperazone-sulbactam against Acinetobacter baumannii strains in terms of bactericidal efficacy and resistance selection. Ann Clin Microbiol Antimicrob (2004) 0.80
Characterization of ESBL (SHV-12) producing clinical isolate of Enterobacter aerogenes from a tertiary care hospital in Nigeria. Ann Clin Microbiol Antimicrob (2010) 0.80
Prevalence and impact of extended-spectrum β-lactamase production on clinical outcomes in cancer patients with Enterobacter species bacteremia. Korean J Intern Med (2014) 0.80
Risk factors and clinical characteristics of patients with qnr-positive Klebsiella pneumoniae bacteraemia. J Antimicrob Chemother (2013) 0.79
Bacteremia caused by Acinetobacter junii at a medical center in Taiwan, 2000-2010. Eur J Clin Microbiol Infect Dis (2012) 0.79
Biomimetic strategies based on viruses and bacteria for the development of immune evasive biomaterials. Biomaterials (2009) 0.79
Can a routine follow-up blood culture be justified in Klebsiella pneumoniae bacteremia? A retrospective case-control study. BMC Infect Dis (2013) 0.78
Comparison between automated system and PCR-based method for identification and antimicrobial susceptibility profile of clinical Enterococcus spp. Rev Inst Med Trop Sao Paulo (2014) 0.78
[Possibilities for the use of 2nd generation cephalosporins in perioperative antibiotic prophylaxis]. Infection (1993) 0.77
Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2015) 0.77
Differences in characteristics between healthcare-associated and community-acquired infection in community-onset Klebsiella pneumoniae bloodstream infection in Korea. BMC Infect Dis (2012) 0.77
Association of mannose-binding lectin 2 gene polymorphisms with persistent Staphylococcus aureus bacteremia. PLoS One (2014) 0.77
Resistance Pattern of Antibiotics in Patient Underwent Open Heart Surgery With Nosocomial Infection in North of Iran. Glob J Health Sci (2015) 0.77
Current status of antibiograms of Listeria ivanovii and Enterobacter cloacae isolated from ready-to-eat foods in Alice, South Africa. Int J Environ Res Public Health (2012) 0.77
Effects of inappropriate empirical antibiotic therapy on mortality in patients with healthcare-associated methicillin-resistant Staphylococcus aureus bacteremia: a propensity-matched analysis. BMC Infect Dis (2016) 0.76
Cymbopogon citratus Protects against the Renal Injury Induced by Toxic Doses of Aminoglycosides in Rabbits. Indian J Pharm Sci (2013) 0.76
Multi-drug resistance in clinical isolates of Gram-negative bacilli in a tertiary care hospital of Assam. Indian J Med Res (2014) 0.75
Impact of empiric weight-based vancomycin dosing on nephrotoxicity and mortality in geriatric patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Pharm Ther (2014) 0.75
Microbiological efficacy and pharmacokinetics of prophylactic antibiotics in liver transplant patients. Antimicrob Agents Chemother (1992) 0.75
Clinical and microbiological characteristics of bloodstream infections due to AmpC β-lactamase producing Enterobacteriaceae: an active surveillance cohort in a large centralized Canadian region. BMC Infect Dis (2014) 0.75
Beyond Susceptible and Resistant, Part I: Treatment of Infections Due to Gram-Negative Organisms With Inducible β-Lactamases. J Pediatr Pharmacol Ther (2011) 0.75
Empiric weight-based vancomycin in intensive care unit patients with methicillin-resistant Staphylococcus aureus bacteremia. Am J Med Sci (2014) 0.75
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med (2000) 23.10
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother (1985) 11.34
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med (2001) 9.08
Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis (2000) 7.80
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med (1996) 6.49
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother (1985) 6.44
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother (1986) 6.20
Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA (1997) 5.85
Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA (1999) 5.26
Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother (1989) 5.09
Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst (1998) 5.05
Pasteurella multocida infections. Report of 34 cases and review of the literature. Medicine (Baltimore) (1984) 5.04
Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis (1986) 4.92
qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother (2006) 4.88
DNA sequence of the region in the genome of herpes simplex virus type 1 containing the genes for DNA polymerase and the major DNA binding protein. Nucleic Acids Res (1985) 4.84
Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med (1993) 4.72
Professional courtesy--current practices and attitudes. N Engl J Med (1993) 4.52
Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother (1988) 4.47
Mechanisms of action of and resistance to ciprofloxacin. Am J Med (1987) 4.46
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 4.42
Inducible resistance to vancomycin in Enterococcus faecium D366. J Infect Dis (1989) 4.34
Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis (2000) 4.24
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med (2000) 4.21
Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol (2001) 4.19
Legionellosis. N Engl J Med (1997) 4.12
New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) (1990) 4.04
Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med (1989) 3.98
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet (2001) 3.94
Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia. Lancet (1993) 3.89
A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. J Bacteriol (1991) 3.70
Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care (1996) 3.70
Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis (1993) 3.68
Vancomycin susceptibility and identification of motile enterococci. J Clin Microbiol (1991) 3.61
Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother (1994) 3.57
Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother (1992) 3.31
Reversible Photoreaction Controlling Expansion of Etiolated Bean-Leaf Disks. Science (1955) 3.31
Ubiquitousness of Legionella pneumophila in the water supply of a hospital with endemic Legionnaires' disease. N Engl J Med (1982) 3.25
Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth. Antimicrob Agents Chemother (1982) 3.15
Serratia marcescens: historical perspective and clinical review. N Engl J Med (1979) 3.08
Methicillin-resistant staphylococcal colonization and infection in a long-term care facility. Ann Intern Med (1991) 3.04
Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA (1998) 3.03
Exposure to bright light and darkness to treat physiologic maladaptation to night work. N Engl J Med (1990) 3.01
Role of pili in the adherence of Pseudomonas aeruginosa to injured tracheal epithelium. Infect Immun (1984) 2.92
Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA (1997) 2.91
Isolation of Legionella pneumophila from hospital shower heads. Ann Intern Med (1981) 2.89
Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis (2001) 2.86
Evidence for mucins and sialic acid as receptors for Pseudomonas aeruginosa in the lower respiratory tract. Infect Immun (1983) 2.86
Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann Intern Med (1981) 2.80
Adherence of mucoid and nonmucoid Pseudomonas aeruginosa to acid-injured tracheal epithelium. Infect Immun (1983) 2.75
DNA hybridization and contour-clamped homogeneous electric field electrophoresis for identification of enterococci to the species level. J Clin Microbiol (1995) 2.69
MOMs (multiples of the median) and DADs (discriminant aneuploidy detection): improved specificity and cost-effectiveness of biochemical screening for aneuploidy with DADs. Am J Obstet Gynecol (1995) 2.67
Infection caused by vancomycin-resistant Streptococcus sanguis II. Antimicrob Agents Chemother (1984) 2.66
Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents (1999) 2.64
A novel chromosomal TEM derivative and alterations in outer membrane proteins together mediate selective ceftazidime resistance in Escherichia coli. J Infect Dis (1990) 2.63
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis (1998) 2.61
A new two-component regulatory system involved in adhesion, autolysis, and extracellular proteolytic activity of Staphylococcus aureus. J Bacteriol (2000) 2.60
Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states. J Clin Microbiol (1993) 2.59
Role of Pseudomonas aeruginosa mucoid exopolysaccharide in adherence to tracheal cells. Infect Immun (1985) 2.54
Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol (2005) 2.53
Resting electrocardiograms as baseline tests: impact on the management of elderly patients. Am J Med (1991) 2.53
An evaluation of machine-learning methods for predicting pneumonia mortality. Artif Intell Med (1997) 2.49
Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis (1996) 2.49
Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Antimicrob Agents Chemother (1986) 2.48
Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med (1986) 2.44
Adherence of Pseudomonas aeruginosa to tracheal cells injured by influenza infection or by endotracheal intubation. Infect Immun (1980) 2.44
Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis (1996) 2.40
Genetic analysis of Pseudomonas aeruginosa adherence: distinct genetic loci control attachment to epithelial cells and mucins. Infect Immun (1992) 2.40
Long-term outcome in children after antenatal intervention for obstructive uropathies. Lancet (1999) 2.37
Utilization of health care services among subgroups of urban homeless and housed poor. J Health Polit Policy Law (1999) 2.36
Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect Immun (1980) 2.35
Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob Agents Chemother (1997) 2.33
Disease due to the Legionellaceae (other than Legionella pneumophila). Historical, microbiological, clinical, and epidemiological review. Medicine (Baltimore) (1989) 2.31
Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. Clin Infect Dis (1996) 2.29
First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother (2005) 2.29
Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? Arch Intern Med (1996) 2.29
A transcriptional activator, FleQ, regulates mucin adhesion and flagellar gene expression in Pseudomonas aeruginosa in a cascade manner. J Bacteriol (1997) 2.29
The Pseudomonas aeruginosa flagellar cap protein, FliD, is responsible for mucin adhesion. Infect Immun (1998) 2.29
Evaluation of housestaff physicians' preparation and interpretation of sputum Gram stains for community-acquired pneumonia. J Gen Intern Med (1991) 2.28
Adherence of Pseudomonas aeruginosa to human tracheobronchial mucin. Infect Immun (1984) 2.28
Roseomonas, a new genus associated with bacteremia and other human infections. J Clin Microbiol (1993) 2.28
Infections caused by Pseudomonas maltophilia with emphasis on bacteremia: case reports and a review of the literature. Rev Infect Dis (1983) 2.27
Bacterial resistance to quinolones: mechanisms and clinical importance. Rev Infect Dis (1989) 2.23
Improvement in hindbrain herniation demonstrated by serial fetal magnetic resonance imaging following fetal surgery for myelomeningocele. JAMA (1999) 2.19
Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenes. J Antimicrob Chemother (1991) 2.18
SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother (2000) 2.15
Diagnosis of Legionnaires' disease. An update of laboratory methods with new emphasis on isolation by culture. JAMA (1983) 2.14
Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med (1999) 2.09
Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med (1996) 2.09
Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis (1999) 2.05
Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures. J Virol (1999) 2.04
Mode of transmission of Legionella pneumophila. A critical review. Arch Intern Med (1986) 2.04
Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus. Antimicrob Agents Chemother (1993) 2.04